Wall Street equity research analysts covering Genelux Corp. (GNLX) maintain positive consensus forecasts, establishing a median twelve-month price target that sits significantly higher than its current trading value. Individual institutional projections range across various price milestones depending on clinical trial catalysts, developmental timelines for its oncolytic immunotherapy candidate, and overall biotechnology market sentiment.